AdaptHealth (NASDAQ:AHCO) Given New $11.00 Price Target at UBS Group

AdaptHealth (NASDAQ:AHCO) had its price objective lowered by analysts at UBS Group from $12.00 to $11.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price would indicate a potential upside of 23.87% from the company’s previous close.

A number of other equities analysts also recently weighed in on AHCO. Royal Bank of Canada lowered their target price on shares of AdaptHealth from $13.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, November 19th. Truist Financial lowered their target price on shares of AdaptHealth from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Canaccord Genuity Group lowered their target price on shares of AdaptHealth from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Robert W. Baird lowered their target price on shares of AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.20.

AdaptHealth Trading Down 0.8 %

NASDAQ AHCO traded down $0.07 on Thursday, hitting $8.88. The company’s stock had a trading volume of 25,380 shares, compared to its average volume of 888,699. The company has a quick ratio of 1.00, a current ratio of 1.24 and a debt-to-equity ratio of 1.34. AdaptHealth has a 1-year low of $7.01 and a 1-year high of $11.90. The company’s 50-day moving average is $9.97 and its 200 day moving average is $10.29. The firm has a market cap of $1.19 billion, a PE ratio of -5.38, a PEG ratio of 1.23 and a beta of 1.12.

Institutional Investors Weigh In On AdaptHealth

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Assetmark Inc. bought a new stake in AdaptHealth in the fourth quarter valued at $28,000. Blue Trust Inc. increased its stake in AdaptHealth by 24.1% in the fourth quarter. Blue Trust Inc. now owns 5,746 shares of the company’s stock valued at $55,000 after purchasing an additional 1,115 shares in the last quarter. Quarry LP increased its stake in AdaptHealth by 4,596.9% in the third quarter. Quarry LP now owns 5,965 shares of the company’s stock valued at $67,000 after purchasing an additional 5,838 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in shares of AdaptHealth by 15.4% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,663 shares of the company’s stock valued at $121,000 after buying an additional 1,690 shares during the last quarter. Finally, CIBC Asset Management Inc acquired a new position in shares of AdaptHealth during the third quarter valued at about $122,000. 82.67% of the stock is owned by institutional investors.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.